GRANTS & FUNDING PROGRAMS AT TRI
In 2015, TRI launched a formal Research Grant Program to support translational research projects based at the institute. The aim is to support researchers progress their discoveries and translate their findings into the clinic. From 2015-2019, TRI awarded $850,000 via 13 grants, with TRI’s partner institutions and industry collaborators matched this funding with a further $1,571,745. TRI is currently reviewing its Grant Program to ensure it maximises the translational support available to researchers based at the institute. The funding opportunity currently available for eligible recipients is:
TRI Research Funding
For teams within TRI seeking funding support for their translational research and/or supporting research grant applications.
If you are interested in applying for support from TRI please contact [email protected] for a link to the application form. Applications need to be made three weeks prior to the submission deadline for the relevant grant applications, and must include:
- What is novel about the proposal and what is its value-add as a TRI investment for the TRI community.
- Previous funding requests to TRI (successful or not) to the same or a different funding body.
- How the application meets each of the criteria against which it will be assessed by TRI.
- Support from the Institute Director at TRI of the primary applicant (CIA).
Read the full eligibility criteria and terms and conditions here
TRI Grant and Funding Recipients
|
Year awarded |
Grant scheme |
Principal Investigator |
Project title |
|
2015 |
Spore |
Dr Michelle Hill |
Obesity-induced Barrett’s oesophagus and associated cancer: mechanisms and diagnostic tools |
|
2015 |
Spore |
Dr Antje Blumenthal |
Towards biomarkers for patient stratification in sepsis |
|
2015 |
Spore |
Prof Rik Thompson |
Portable, single-sided MRI for routine, low-cost analysis of mammographic density |
|
2015 |
Spore |
Prof Ken O'Byrne |
Nucleoplasmin (NPM)1 a critical repair protein required for genomic stability |
|
2016 |
Spore |
A/Prof Jyotsna Batra |
Novel MicroRNA’s as potential targets for treating prostate cancer |
|
2016 |
Spore |
A/Prof Chamindie Punyadeera |
Circulating Tumour Cells as Biomarkers to Identify Head and Neck Cancer Patients for PD1 Therapy |
|
2018 |
Spore |
Prof Gerald Holtmann |
Modulation of the GI Microbiome with probiotics to treat constipation |
|
2018 |
Spore |
Prof John Hooper |
Theranostic biomolecules for improved diagnosis and treatment of pancreatic cancer |
|
2018 |
Spore |
Dr Arutha Kulasinghe |
Can liquid biopsy provide predictive biomarkers for checkpoint inhibitor response in Non-Small Cell Lung Cancer? |
|
2018 |
Spore |
Prof Peter Soyer |
Towards clinical diagnosis of inflammatory skin rashes using minimally‐invasive micro-sampling technologies |
|
2019 |
Spore |
A/Prof Jyotsna Batra |
Improving the PSA test to detect all lethal prostate cancers |
|
2019 |
Spore |
Prof Ben Panizza |
Therapeutic Potential for the Treatment of Adenoid Cystic Carcinoma (ACC) |
|
2019 |
Drive |
Prof Sandro Porceddu |
Durvax Trial: A Phase 1b, single centre, open label study of a therapeutic Human Papilomavirus (HPC) DNA vaccine co-administered with anti-PD-L1 immunotheraphy, Duravalumab (MED14736), for recurrent and/or metastatic HPV-related oropharnygeal cancer |
FOR EXTERNAL GRANT AND FUNDING
Looking for funding for your research project? Visit the Grant and Funding list page for some helpful links to grant and funding opportunities relevant to research projects at TRI.
